Savvy Trades and Investments

[researcher59]

GERN -.42 to 2.77, Imetelstat has been around for over a decade and they've failed to find a use for it, until maybe now ? They are a serial diluter, share count up 100% in just the last 3 years and recently settled a class action lawsuit for misleading investors. It remains to be seen whether the FDA approves this drug and if so what the annual revenues will be since it's a rare cancer. At best some modest revenues in 2024, but profitability is years away, if ever.

Good luck, maybe it gets a bounce back to $3.50 once the capital raise completes, but I'd use that as a selling opportunity.